未登录.png)
分享.png)
收藏A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer一项比较氨柔比星与多西他赛在先前治疗的非小细胞肺癌患者中的随机，开放标签，III期试验
Yoshioka, H.; Katakami, N.; Okamoto, H.; Iwamoto, Y.; Seto, T.; Takahashi, T.; Sunaga, N.; Kudoh, S.; Chikamori, K.; Harada, M.; Tanaka, H.; Saito, H.; Saka, H.; Takeda, K.; Nogami, N.; Masuda, N.; Harada, T.; Kitagawa, H.; Horio, H.; Yamanaka, T.; Fukuoka, M.; Yamamoto, N.; Nakagawa, K. 分享 收藏 Antitumor activity of ASP8273, an irreversible mutant selective EGFR-TKI, in NSCLC patients with tumors harboring EGFR activating mutations and T790M resistance mutation不可逆突变选择性egfr-tki ASP8273在具有EGFR激活突变和T790M耐药突变的NSCLC患者中的抗肿瘤活性Murakami, H.; Nokihara, H.; Shimizu, T.; Seto, T.; Keating, A.; Krivoshik, A.; Uegaki, K.; Morita, S.; Nakagawa, K.; Fukuoka, M. 分享 收藏 Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancerSoria, J. -C.; Mauguen, A.; Reck, M.; Sandler, A. B.; Saijo, N.; Johnson, D. H.; Burcoveanu, D.; Fukuoka, M.; Besse, B.; Pignon, J. -P. 分享 收藏 Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402)Niho, S.; Ohe, Y.; Ishikura, S.; Atagi, S.; Yokoyama, A.; Ichinose, Y.; Okamoto, H.; Takeda, K.; Shibata, T.; Tamura, T.; Saijo, N.; Fukuoka, M. 分享 收藏 Randomized Phase II Trial of Zoledronic Acid in Combination With Docetaxel in Previously Treated Non-small Cell Lung Cancer (NSCLC) Patients With Bone Metastases - Result of a West Japan Oncology Group StudyHirai, F.; Murakami, H.; Yamamoto, N.; Yamanaka, T.; Okamoto, I.; Sawa, T.; Hirashima, T.; Takeda, K.; Fukuoka, M.; Nakagawa, K. 分享 收藏 分享 收藏 Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugsIwasa, T.; Okamoto, I.; Takezawa, K.; Yamanaka, K.; Nakahara, T.; Kita, A.; Koutoku, H.; Sasamata, M.; Hatashita, E.; Yamada, Y.; Kuwata, K.; Fukuoka, M.; Nakagawa, K. 分享 收藏 Phase III Study of Mitomycin/Vindesine/Cisplatin (MVP) vs. Weekly Irinotecan/Carboplatin (IC) or Weekly Paclitaxel/Carboplatin (PC) with Concurrent Thoracic Radiotherapy (TRT) for Unresectable Stage III Non-small-cell Lung Cancer (WJTOG0105); Special Reference on Delivery of TRTNishimura, Y.; Tsujino, K.; Satouchi, M.; Tanaka, M.; Kodaira, T.; Kokubo, M.; Fukuda, H.; Yamamoto, N.; Nakagawa, K.; Fukuoka, M. 分享 收藏 Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxelSekine, I.; Ichinose, Y.; Nishiwaki, Y.; Yamamoto, N.; Tsuboi, M.; Nakagawa, K.; Shinkai, T.; Negoro, S.; Imamura, F.; Eguchi, K.; Takeda, K.; Itoh, Y.; Tamura, T.; Saijo, N.; Fukuoka, M. 分享 收藏 Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)吉非替尼治疗表皮生长因子受体突变的晚期非小细胞肺癌的多中心前瞻性II期试验: 西日本胸腔肿瘤学组试验 (WJTOG0403) 的结果Tamura, K.; Okamoto, I.; Kashii, T.; Negoro, S.; Hirashima, T.; Kudoh, S.; Ichinose, Y.; Ebi, N.; Shibata, K.; Nishimura, T.; Katakami, N.; Sawa, T.; Shimizu, E.; Fukuoka, J.; Satoh, T.; Fukuoka, M. 分享 收藏 Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor statusAkashi, Y.; Okamoto, I.; Iwasa, T.; Yoshida, T.; Suzuki, M.; Hatashita, E.; Yamada, Y.; Satoh, T.; Fukuoka, M.; Ono, K.; Nakagawa, K. 分享 收藏 The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivoAkashi, Y.; Okamoto, I.; Suzuki, M.; Tamura, K.; Iwasa, T.; Hisada, S.; Satoh, T.; Nakagawa, K.; Ono, K.; Fukuoka, M. 分享 收藏 Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in JapanOhe, Y.; Ohashi, Y.; Kubota, K.; Tamura, T.; Nakagawa, K.; Negoro, S.; Nishiwaki, Y.; Saijo, N.; Ariyoshi, Y.; Fukuoka, M. 分享 收藏 分享 收藏 分享 收藏 Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer氨柔比星和顺铂在先前未经治疗的广泛期小细胞肺癌患者中的i-ii期研究Ohe, Y; Negoro, S; Matsui, K; Nakagawa, K; Sugiura, T; Takada, Y; Nishiwaki, Y; Yokota, S; Kawahara, M; Saijo, N; Fukuoka, M; Ariyoshi, Y 分享 收藏 分享 收藏 分享 收藏 Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors选择性口服表皮生长因子受体酪氨酸激酶抑制剂吉非替尼 ('Iressa'，ZD1839) 在日本实体恶性肿瘤患者中的I期药代动力学试验Nakagawa, K; Tamura, T; Negoro, S; Kudoh, S; Yamamoto, N; Yamamoto, N; Takeda, K; Swaisland, H; Nakatani, I; Hirose, M; Dong, RP; Fukuoka, M 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
